Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularINJECTIONGeneric

LEUSTATIN

CLADRIBINE

Standard Dose
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview LEUSTATIN is listed in Drugs@FDA under application 020229 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CLADRIBINE Form and strength INJECTABLE;INJECTION - 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2012-08-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview LEUSTATIN is listed in Drugs@FDA under application 020229 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CLADRIBINE Form and strength INJECTABLE;INJECTION - 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2012-08-02 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
LEUSTATIN (CLADRIBINE) | Drug Monograph | MedicHelpline